tiprankstipranks
MaxCyte Inc Announces Cenk Sumen’s Transition and Severance Terms
Market News

MaxCyte Inc Announces Cenk Sumen’s Transition and Severance Terms

MaxCyte Inc (MXCT) has released an update to notify the public and investors about its officers.

Pick the best stocks and maximize your portfolio:

Cenk Sumen, Ph.D., concluded his role as Chief Scientific Officer of MaxCyte, Inc. on January 23, 2024. Per his Severance Agreement, he will receive his base salary for nine months post-termination and health care continuation contributions. These benefits depend on his adherence to a release of claims agreement. Dr. Sumen will continue his association with MaxCyte as a member of the Scientific Advisory Board.

For further insights into MXCT corporate activity, check out TipRanks’ Insiders Trading Activity page.

Related Articles
TipRanks UK Auto-Generated NewsdeskMaxCyte, Inc. Announces Change in Major Holdings by BlackRock
TipRanks UK Auto-Generated NewsdeskMaxCyte Announces Change in Major Shareholdings
TheFlyMaxCyte to reduce workforce by 15% following internal review
Go Ad-Free with Our App